FrancophonIA/ELRC3.0 huggingface dataset:
English: In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
Croatian: U studiji CURE, s klopidogrelom uz ASK nije bilo povećanja broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
English: Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
Croatian: Farmakogenetika: u bolesnika koji su slabi CYP2C19 metabolizatori, kod preporučenih doza klopidogrela, stvara se manja količina aktivnog metabolita te ima manji učinak na funkciju trombocita.
English: Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Croatian: U skladu s gore navedenim rezultatima, u metaanalizi koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazano je da je izloženost aktivnom metabolitu smanjena za 28% za umjerene metabolizatore te 72% za slabe metabolizatore, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena s razlikama za vrijednosti IPA-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
English: There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Croatian: Nije bilo statistički značajne razlike u stopama fatalnih krvarenja (1,1% u skupini klopidogrel + ASK i 0,7% u skupini placebo + ASK) i hemoragijskog moždanog udara (0,8% naspram 0,6%) među skupinama.
English: This statistically significant difference was mainly driven by fewer bleeding events, with no difference reported in ischaemic endpoints (p=0.36), while BARC ≥ 2 bleeding occurred less frequently in the de-escalated DAPT group (4.0 %) versus 14.9 % in the unchanged DAPT group (p<0.01).
Croatian: Ova statistički značajna razlika uglavnom je posljedica manjeg broja događaja krvarenja, bez prijavljene razlike u ishemijskim mjerama ishoda (p=0,36), dok se BARC stupanj krvarenja ≥ 2 javljao rjeđe u skupini s de-eskaliranim DAPT-om (4,0%) u odnosu na skupinu sa nepromijenjenim DAPT-om (p < 0,01).
English: However, if you are concerned by your bleeding, you should contact your doctor straightaway (see ‘Warnings and precautions').
Croatian: Ukoliko ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 2. "Upozorenja i mjere opreza").
English: How to take Grepid
Croatian: Kako uzimati Grepid
English: Therefore, the guided de-escalation arm had patients on either prasugrel (40 %) or clopidogrel (60 %).
Croatian: Dakle, u skupini sa deeskalacijom vođenoj na temelju vrijednosti HPR-a, bolesnici su primali ili prasugrel (40%) ili klopidogrel (60%).
English: In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6 % for clopidogrel plus ASA, and 6.3 % for placebo plus ASA.
Croatian: U bolesnika koji su terapiju nastavili primati i unutar 5 dana do ugrađivanja premosnice, stopa krvarenja bila je 9,6% za klopidogrel uz ASK, odnosno 6,3% za placebo uz ASK.
English: The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥ 2 at 12 months) was met showing non-inferiority.
Croatian: Primarna mjera ishoda (kombinirana incidencija kardiovaskularne smrti, infarkta miokarda, moždanog udara i BARC stupnja krvarenja ≥ 2 u 12 mjeseci) je ostvarena te je pokazala neinferiornost.
English: In all aluminium blisters, this medicinal product does not require any special storage conditions.
Croatian: Lijek u aluminijskim blisterima, ne zahtijeva posebne uvjete čuvanja.
English: Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese
Croatian: Poremećaji imunološkog sustava serumska bolest, anafilaktoidne reakcije križno reaktivna preosjetljivost na lijekove iz skupine tienopiridinima (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)*, autoimuni inzulinski sindrom koji može dovesti do teške hipoglikemije, osobito u bolesnika s podtipom HLA DRA4 (češći u japanskoj populaciji)*
English: Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4).
Croatian: Oralni antikoagulansi: istodobna primjena klopidogrela i oralnih antikoagulansa se ne preporučuje jer se može povećati intenzitet krvarenja (vidjeti dio 4.4.).
English: - The active substance is clopidogrel.
Croatian: Djelatna tvar je klopidogrel.
English: Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz.
Croatian: Lijekovi koji su jaki iliumjereni inhibitori CYP2C19 uključuju, primjerice, omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin, iefavirenz.
English: Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, druginduced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms
Croatian: bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
English: Very rare, not known* (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Croatian: DRESS), eritematozni ili eksfolijativni osip, urtikarija, ekcem, lichen planus
English: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel.
Croatian: S obzirom da se klopidogrel do svog aktivnog metabolita djelomično metabolizira preko CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost ovog enzima rezultirati smanjenim razinama aktivnog metabolita klopidogrela.
English: 15351 Pallini Attiki Greece
Croatian: 15351 Pallini Attiki Grčka ili
English: You should specially tell your doctor if you take: - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscles or joints o heparin or any other injectable medicine used to reduce blood clotting o ticlopidine, other antiplatelet agent o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression - omeprazole or esomeprazole, medicines to treat upset stomach - fluconazole or voriconazole, medicines to treat fungal infections
Croatian: Posebno je važno obavijestiti liječnika ako uzimate - lijekove koji mogu povećati rizik od krvarenja, na primjer: o oralne antikoagulanse, lijekove koji smanjuju zgrušavanje krvi, o nesteroidne protuupalne lijekove, koji se obično primjenjuju za liječenje bolnih i/ili upalnih stanja mišića ili zglobova, o heparin ili bilo koji drugi lijek koji se daje putem injekcije za smanjivanje zgrušavanja krvi, o tiklopidin, drugi antitrombocitni lijek, o selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin ili fluvoksamin), lijekove koji se obično koriste za liječenje depresije, - omeprazol ili esomeprazol, lijekove za smanjenje želučanih tegoba, - flukonazol ili vorikonazol, , lijekovi koji se primjenjuju za liječenje gljivičnih infekcija, - efavirenz, lijek koji se primjenjuje za liječenje HIV (virus humane imunodeficijencije) infekcija, - karbamazepin, lijek koji se primijenjuje za liječenje nekih oblika epilepsije,
English: Grepid 75 mg film-coated tablets clopidogrel
Croatian: Grepid 75 mg filmom obložene tablete klopidogrel
English: A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Croatian: U križnoj studiji na 40 zdravih osoba, po 10 iz svake skupine CYP2C19 metabolizatora (ultrabrzi, brzi, umjereni i slabi), procijenjen je farmakokinetički i antitrombocitni odgovor primjenom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te primjenom doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
English: Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food.
Croatian: Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba): žutica, jaka bol u trbuhu s ili bez bolova u leđima, vrućica, teškoće pri disanju, ponekad povezane s kašljem, generalizirane alergijske reakcije (primjerice, sveukupni osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima, mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka, zbunjenost; halucinacije; bol u zglobovima bol u mišićima, poremećaj okusa ili gubitak osjeta okusa hrane.
English: The clinical benefit provided by the more potent P2Y12 inhibitors, ticagrelor and prasugrel, in their pivotal studies is related to a significant reduction in recurrent ischaemic events (including acute and subacute stent thrombosis (ST), myocardial infarction (MI) and urgent revascularization).
Croatian: Klinička korist koju su u pivotalnim ispitivanjima pokazali potentniji inhibitori P2Y12, tikagrelor i prasugrel, povezana je sa značajnim smanjenjem rekurentnih ishemijskih događaja (uključujući akutnu i subakutnu trombozu stenta, infarkt miokarda i hitnu revaskularizaciju).
English: Grepid 75 mg film-coated tablets
Croatian: Grepid 75 mg filmom obložene tablete
English: - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections - carbamazepine, a medicine to treat some forms of epilepsy - moclobemide, medicine to treat depression - repaglinide, medicine to treat diabetes - paclitaxel, medicine to treat cancer - anti-retroviral medicines (medicines to treat HIV infections).
Croatian: - moklobemid, lijek za liječenje depresije, - repaglinid, lijek za liječenje dijabetesa, - paklitaksel, lijek za liječenje raka, - antiretrovirusne lijekove (lijekovi za liječenje infekcije HIV-om).
English: Cellulose, microcrystalline Hydroxypropylcellulose (E463) Mannitol (E421) Crospovidone (type A) Citric acid monohydrate Macrogol 6000
Croatian: Jezgra tablete celuloza, mikrokristalična hidoksipropilceluloza (E463) manitol (E421) krospovidon (tip A) makrogol 6000 citratna kiselina hidrat stearatna kiselina talk
English: The most common side effect reported with Grepid is bleeding.
Croatian: Najčešća nuspojava Grepida jest krvarenje.
English: Rare side effects (may affect up to 1 in 1,000 people): Vertigo, enlarged breasts in males.
Croatian: Rijetke nuspojave (mogu se javiti u manje od 1 na 1000 osoba): vrtoglavica, povećanje grudi u muškaraca.
English: In PVC/PE/PVDC/aluminium blisters, store below 25°C.
Croatian: U PVC/PE/PVDC/aluminij blisterima, čuvati na temperaturi ispod 25°C.
English: In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Croatian: U tzv. post-hoc analizi 2 172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom, pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar) kao i značajno smanjenje relativnog rizika od 23,9% za drugi koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar ili refraktorna ishemija).
English: How to store Grepid
Croatian: Kako čuvati Grepid
English: If Grepid is supplied in PVC/PE/PVDC/aluminium blisters, store below 25°C.
Croatian: Ako je Grepid opremljen u PVC/PE/PVDC/aluminijske blistere, čuvati na temperaturi ispod 25°C.
English: As a precaution, concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (za popis inhibitori CYP2C19 (za popis inhibitora CYP2C19 vidjeti dio 4.5., također vidjeti dio 5.2.).
English: Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Grepid:
Croatian: Ako se na Vas odnosi bilo koje od dolje navedenih stanja morate obavijestiti liječnika, prije nego što uzmete Grepid:
English: ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics.
Croatian: Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te sa ili bez trombolitika.
English: BLISTER/ 10, 14, 28, 30, 50, 84, 90 or 100 film-coated tablets
Croatian: BLISTER / 10, 14, 28, 30, 50, 84, 90 ili 100 filmom obloženih tableta
English: In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]).
Croatian: U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
English: Packs of 10, 14, 28, 30, 50, 84, 90 or 100 film-coated tablets.
Croatian: Pakiranja s 10, 14, 28, 30, 50, 84, 90 ili 100 filmom obloženih tableta.
English: − Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA)
Croatian: Bolesnici s akutnim koronarnim sindromom: − Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
English: The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Croatian: Broj bolesnika koji su doživjeli primarni ishod (kardiovaskularna smrt, infarkt miokarda ili moždani udar) bio je 582 (9,3%) u skupini koja je primala klopidogrel i 719 (11,4%) u skupini koja je primala placebo, uz 20%-tno smanjenje relativnog rizika (95% CI od 10% do 28%; p=0,00009) u skupini koja se liječila klopidogrelom (17% smanjenje relativnoga rizika u bolesnika koji su liječeni konzervativno, 29% u bolesnika podvrgnutih perkutanoj transluminalnoj koronarnoj angioplastici (PTCA) s ili bez ugradnje stenta i 10% za bolesnike kojima je obavljeno aortokoronarno premoštenje (CABG, engl.
English: Calendar days Mon
Croatian: Dani u tjednu Pon
English: Tel.: +48 22 822 93 06
Croatian: Symphar Sp. z o.o. Tel.: +48 22 822 93 06
English: - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) - a recent serious injury - a recent surgery (including dental).
Croatian: • Ako postoji opasnost od krvarenja poput - medicinskih stanja kod kojih postoji opasnost od unutrašnjeg krvarenja (kao što je želučani čir), - poremećaja krvi zbog čega ste skloni unutrašnjim krvarenjima (krvarenje u tkivima, organima ili zglobovima), - nedavne teške ozljede, - nedavnog kirurškog zahvata (uključujući stomatološke zahvate), - planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
English: If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Grepid.
Croatian: Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja Grepida.
English: Tabulated list of adverse reactions
Croatian: Tabični popis nuspojava
English: If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine.
Croatian: Dok uzimate ovaj lijek, ne biste smjeli dojiti.Ako dojite ili planirate dojiti, razgovarajte sa svojim liječnikom prije uzimanja ovog lijeka.
English: Therefore, concomitant use should be undertaken with caution (see section 4.4).
Croatian: Zbog toga, kod istodobne primjene potreban je oprez (vidjeti dio 4.4.).
English: Marketing Authorisation Holder Pharmathen S.A., 6 Dervenakion
Croatian: Pharmathen S.A., 6 Dervenakion
English: If HPR ≥ 46 units, the patients were escalated back to prasugrel 5 or 10 mg/d for 11.5 months; if HPR < 46 units, the patients continued on clopidogrel 75 mg/d for 11.5 months.
Croatian: Ako je HPR bio < 46 jedinica bolesnici su nastavili liječenje klopidogrelom u dozi od 75 mg/dan još 11,5 mjeseci.
English: Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1,309), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1,309), in combination with ASA (<100 mg/day).
Croatian: Bolesnici su bili randomizirani tako da primaju prasugrel u dozi od 5 ili 10 mg/dan (dan 0-14) (n=1309) ili prasugrel u dozi od 5 ili 10 mg/dan (dan 0-7) nakon čega su prebačeni na de-eskaliranu terapiju - klopidogrel u dozi od 75 mg/dan (dan 8-14) (n=1309) u kombinaciji s acetilsalicilatnom kiselinom (< 100 mg/dan).
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Croatian: Broj bolesnika koji su doživjeli koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar ili refraktorna ishemija) bio je 1035 (16,5%) u skupini koja je primala klopidogrel, a 1187 (18,8%) u skupini koja je primala placebo, što znači smanjenje relativnoga rizika od 14% (95% CI: 6% do 21%, p=0,0005) u skupini koja je primala klopidogrel.
English: Lot
Croatian: Uto
English: The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization and BARC (Bleeding Academic Research Consortium) bleeding ≥ 2 at 1 year post-ACS, occurred in 43 patients (13.4 %) in the de-escalated DAPT group and in 85 patients (26.3 %) in the unchanged DAPT group (p<0.01).
Croatian: Bleeding Academic Reasearch Consortium) stupnja krvarenja ≥ 2 u prvoj godini nakon akutnog koronarnog sindroma dogodio se u 43 bolesnika (13,4%) u skupini sa de-eskaliranim DAPT-om i u 85 bolesnika (26,3%) u skupini s nepromijenjenim DAPT-om.
English: Driving and using machines Grepid is unlikely to affect your ability to drive or to use machines.
Croatian: Grepid ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
English: In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).
Croatian: ASK (75-100 mg dnevno) treba započeti i nastaviti davati u kombinaciji s klopidogrelom (vidjeti dio 5.1).
English: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece
Croatian: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Grčka
English: In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Croatian: U analizi ITT (engl. 'intention to treat') zabilježeno je 939 slučajeva u skupini koja je primala klopidogrel, a 1020 u skupini koja je primala ASK (realtivno smanjenje rizika, RRR - engl. relative risk reduction = 8,7% [95% CI: 0,2 do 16,4]; p=0,045) što, odgovara broju od dodatnih 10 bolesnika kojima je spriječen novi ishemijski događaj, na svakih 1000 bolesnika liječenih 2 godine [CI: 0 do 20]. Analiza ukupne smrtnosti, sekundarnog ishoda studije nije pokazala značajnu razliku između klopidogrela (5,8%) i ASK (6,0%).
English: Teл.
Croatian: Čet
English: - You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing.
Croatian: Liječnik će Vam propisati i acetilsalicilatnu kiselinu (tvar koju sadrže mnogi lijekovi za ublažavanje boli i snižavanje povišene temperature, kao i oni za sprječavanje stvaranja krvnih ugrušaka). - imate nepravilne otkucaje srca, stanje koje se zove "fibrilacija atrija", a ne možete uzimati lijekove poznate kao ''oralni antikoagulansi'' (antagonisti vitamina K), koji sprječavaju stvaranje novih ugrušaka te rast postojećih ugrušaka.
English: Or
Croatian: I
English: Glenmark Pharmaceuticals B.V. Tel: +31 (0)20 561 6127
Croatian: Tel: +31 (0)20 561 6127
English: Manufacturers Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece
Croatian: Nositelj odobrenja Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Grčka
English: - The other ingredients are (see section 2 ‘Grepid contains lactose'): Tablet core: Microcrystalline cellulose, hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, macrogol 6000, stearic acid, talc Tablet coating: Hypromellose (E464), iron oxide red (E172), lactose monohydrate, triacetin (E1518), titanium dioxide (E171)
Croatian: Jezgra tablete: mikrokristalična celuloza, hidoksipropilceluloza (E463), manitol (E421), krospovidon (tip A), citratna kiselina hidrat, makrogol 6000, stearatna kiselina, talk.